Sopharma Group has acquired two pharmaceutical products in Poland
Sopharma Group has acquired Coffepirine and Kopiryna, two highly recognized medicines to treat headache. The acquisition will further expand the market presence of Sopharma Group in the Polish market and support the promising potential of the two pharmaceutical drugs.
Sopharma Group is a leading producer and distributor of healthcare products in the CEE, with a vertically integrated business model running through the whole value chain, with its own R&D, manufacturing and wholesale and retail distribution. The company is present in 33 countries and has a portfolio consisting of more than 200 products.
Coffepirine and Kopiryna are OTC analgesics with APIs based on a combination of acetylsalicylic acid and caffeine, which have helped the Polish public to treat headaches for decades. The drugs are developed and manufactured by Medicofarma, a well-known Polish pharmaceuticals company.
Medicofarma is a pharmaceutical manufacturing company focusing on contract manufacturing of pharmaceuticals, medicinal products and dietary supplements. The company has a modern factory equipped with state-of-the-art technology and meets all GMP requirements.
Oaklins’ team in Bulgaria acted as buy-side advisor to Sopharma Group, leading the transaction process, deal structuring and negotiations, and assisting throughout the acquisition process.
Talk to the deal team
Related deals
CARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
Learn morePrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Learn moreCara Care has been acquired by Mahana Therapeutics
Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.
Learn more